Part 3 Agents Used in Hyperlipidemia

1

Part 1Lipid regulating agents

调血脂药

浙江大学医学院药理学系

张世红

shzhang713@zju.edu.cn

Lipid metabolism

(30%)

(70%)

Classification of Dyslipidemia

TypeElevated lipo-protein

Ch TG Risk of CHD

I CM + +++ /IIa LDL ++ / High IIb LDL+VLDL ++ ++ High III βVLDL ++ ++ ModerateIV VLDL + ++ ModerateV CM+VLDL + ++ /

3Ch: cholesterol; TG: triglyceride; /: no change

Correlation Between Cholesterol Levels and CHD Death

4

0

2

4

6

8

10

12

14

16

18

140 160 180 200 220 240 260 280 300Serum total cholesterol (mg/dL)

Age-adjusted 6-yearCHD death rateper 1000 men

Martin MJ et al. Lancet. 1986;II:933-936.

n=325,000 men

Role:For every 1% increasein LDL-C, there is a 1% increase in CHD events

• Lipids of HDL come from CM and VLDL during lipolysis, or acquires cholesterol from peripheral tissues.

• HDL brings cholesterol back to liver or transfers to IDL

• The role of HDL is keeping the cholesterol homeostasis of cells

• Low HDL is an independent risk factor for CHD.

5

HDL (high density lipoprotein)

Strategies to regulate serum lipid

1. Identify patients at risk

- Routine screening of serum cholesterol

- Assessment of contributing risk factors

2. Non-pharmacologic therapy

- Diet modification

- Lifestyle modification

3. Pharmacological therapy6

7中国营养学会推荐

中国居民平衡膳食宝塔

Drugs used for dyslipidemia HMG CoA reductase inhibitors (他汀类): lovastatin洛伐他汀, etc.

羟甲基戊二酸单酰辅酶A还原酶抑制剂

Cholesterol absorption inhibitors: ezetimide依折麦布,

Bile acid binding resins (树脂类, colestryramine, colestipol)

Fibrates (贝特类): gimfibrozil吉非贝齐, feinofibrate非诺贝特

Nicotinic acids (烟酸类): nicotinic acid烟酸, acipimox阿昔莫司

Antioxidants (抗氧化剂): probucol普罗布考

Others: EPA (廿碳戊烯酸), DHA(廿二碳六烯酸), linoleic acid (亚

油酸) , policosanol多廿烷醇,

8

9

Action sites of drugs for hypercholesterolemia

10

HMG-CoA Reductase Inhibitors (Statins)

Lovastatin（洛伐他汀）

Simvastatin（辛伐他汀）

Pravastatin （普伐他汀）

Atorvastatin（阿伐他汀，立普妥）

Fluvastatin（氟伐他汀）

Rosuvastatin（瑞舒伐他汀）

……

StatinsMechanisms:

• Structural analogs of the HMG-CoA, inhibit synthesis of Ch.

• Increase in high-affinity LDL receptors

11

（异戊二烯焦磷酸）

鲨烯

甲羟戊酸

类异戊二烯

StatinsPharmacological effects:• Lipid regulating effects: reduce LDL, VLDL, TC,

TG, increase HDL.

12

StatinsPharmacological effects:• Lipid regulating effects: reduce LDL, VLDL, TC, TG,

increase HDL.

• Pleiotropic effects多效性作用: ameliorate the functions of vascular endothelial cells, inhibit the proliferation and migration of VSMCs, inhibit the function of inflammatory cells and platelet aggregation, antioxidant effect, bone metabolism (formation↑, absorption↓), renal protection

13

Indications:– Hypercholesterolemia and associated diseases

– Renal syndrome

– Reduce restenosis after PTCA, reduce rejection rate after organ transplantation, treatment of osteoporosis.

14

Statins

Statins– Due to the first pass hepatic extraction, the major

effect is in the liver

– Enhanced if taken with food (except for pravastatin –

taken without food)

– Taken in the evening (Why?)

– May need to increase the dosage during the

treatment period (Why?)

15

Summary of Pharmacokinetics of Statins

McTaggart F et al. Am J Cardiol 2001;87(suppl):28B-32B; Knopp RH. N Engl J Med 1999;341:498-511.

Drugs

Pravastatin 44.1 1-2 No17%

Atorvastatin 8.2 Yes14~14%

Fluvastatin 27.6 No1-224%

Simvastatin 11.2 Yes1-2< 5%

Rosuvastatin 5.4 19 No~20%

16

Adverse effects– Statins are pregnancy category X– Rash, GI disturbances (dyspepsia, cramps,

flatulence, constipation, abdominal pain) – Myopathy (0.5% of pts)

»Risk highest with lovastatin and especially in combination with fibrates (贝特类降脂药)

– CYP3A4 or CYP2C9 drug interactions– Hepatotoxicity– Increase the risk of diabetes (slightly)

17

Statins

Risk factors for myopathy• Advanced age

– > 80 yo– Women > men

• Multisystem disease– diabetes, thyroid,

liver• Perioperative period• Major trauma• Electrolyte imbalance

• Metabolic acidosis• Hypoxia• Infection• Large quantities of

grapefruit juice (>1 L/day)• Alcohol abuse• Drug interactions

18Jacobson TA. Expert Opin Drug Saf 2003;2:269-86Davidson MH. Am J Cardiol 2002;90 (suppl):50K-60K

Statins

Cholesterol absorption inhibitors

19

• Ezetimibe (依折麦布): inhibits intestinal cholesterol absorption

• Resins (cholestyramine, 考来烯胺; colestipol, 考来替泊) : bind bile acids

Ezetimibe• Mechanisms and effects:

– Blocks cholesterol absorption at the intestinal brush border (Niemann-Pick C1-like 1 protein, NPC1L1)

– Reduces LDL (upregulates LDL receptors)

20

Ezetimibe ↓ 18 ↑ 1 ↓ 8

Resins ↓ 15-30 ↑ 3-5 ↑ /Neutral

Statins ↓ 18-60 ↑ 5-15 ↓ 7-30

Fibrates ↓ 5-20 ↑ 10-35 ↓ 20-50

Niacin ↓ 5-25 ↑ 15-35 ↓ 20-50

Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.JAMA. 2001;285:2486-2497.

LDL-C HDL-C TGDrug class (% ∆) (% ∆) (% ∆)

21

Ezetimibe

• Mechanisms and effects:

– No effect on absorption of lipid-soluble vitamins– Minimal systemic exposure and very well tolerated– Additive in combination with statins with monitoring ALT

1-STEP COADMINISTRATION

3-STEP TITRATION

% Reduction in LDL-C

5%-6% 5%-6%

Statin – starting dose 1st 2nd 3rd

5%-6%

Statin – starting dose + Zetia10 mg

15%-18%

Doubling

• Mechanisms:- Bind to bile acid in the intestines, interrupting enterohepatic circulation (肠肝循环) and increasing bile acid production and fecal excretion with cholesterol.

- LDL receptors

• Efficacy:LDL 15-30%

22

Resins

23

Indications:

- High LDL- Pruritis due to cholestasis胆汁淤积症 and bile salt accumulation;- Diarrhea after post-cholecystectomy胆囊切除术

- May be useful in digitalis洋地黄 toxication

Resins

Adverse effects:

- Constipation, bloating, indigestion, nausea, large doses may impair absorption of fats (脂肪痢) or fat soluble vitamins (A, D, E, and K)

- Affect absorption of other drugs, should be given 1 hour before the resin or 4 hours after.

24

Gemfibrozil（吉非贝齐）

Fenofibrate（非诺贝特，力平之）

Benzafibrates（苯扎贝特）

Fibrates

• Mechanisms• Act as PPARα ligands (peroxisome proliferator-activated

receptor-α, 过氧化物酶体增殖物激活受体α) PPARα, a nuclear receptor that regulates lipid metabolism

and glucose homeostasis

VLDL catabolism by lipoprotein lipase

Apo CIII, VLDL production

apoA I and II, HDL

Antioxidant, antiproliferation and antiinflammation effects

25

Fibrates

• Efficacy:TG 40-55%, HDL 10-25%, LDL + 10%

• Indications:High TG and/or low HDL

• Adverse effects:Rashes, GI upset, gallstones (increase biliary cholesterol saturation)Use with caution in pts with biliary tract disease, hepatic or renal dysfunctionIncrease risk of statin-induced myopathyDisplaces warfarin from plasma albumin due to highly protein bound property.

26

Fibrates

Nicotinic acid and Acipimox

27

• Nicotinic acid (烟酸, Vitamin B3)

• Acipimox (阿昔莫司)

Increased apo-B 100 clearance apo B-100

apo C

apo E↓ VLDL

↓ VLDLRemnant

↓ LDL

Liver

Decreased VLDLProduction

Other sites Increased VLDLclearance through LPL

• Mechanisms and effects- Suppress synthesis of VLDL, IDL, & LDL in the liver.- Increase clearance of VLDL via the LPL pathway, TG catabolism

- May HDL catabolism

28

Nicotinic acid and Acipimox

• Efficacy:TC 25%, LDL 10-25%, HDL 10-40%, TG 20-50%

• Indications:• High LDL (and/or VLDL) • Combined hyperlipidemia (including low levels of HDL--Niaspan® , approved for elevating HDL levels)

Adverse effects:– Flushing (very uncomfortable, aspirin may helpful)– Pruritis, rashes, dry skin– Nausea and abdominal discomfort

29

– Rare hepatotoxicity

– Hyperuricemia (occurs in about 1/5 of pts, occasionally

precipitates gout)

– Carbohydrate tolerance may be moderately impaired

(reversible hyperglycemia)

Nicotinic acid and Acipimox

Probucol (普罗布考)• Action: Taken up by LDL particles and endothelial cells,

inhibits oxidation of LDL, decreases atherosclerotic plaque formation; small reduction in LDL; greater reduction in HDL.

• Clinical uses: may be used in combination therapy with other drugs that lower serum LDL.

• Disadvantages: not effective in single drug therapy; no long term clinical data.

30

Antioxidants

Polyunsaturated fatty acids: EPA, DHA (ω-3 PUFAs)• Reduce TG

• Only highly purified preparation (>96%) approved.

• Risk in increase of LDL (more strongly associated wih coronary artery diseases)

• The effects on cardiac morbidity or mortality is unproven(although there is epidemiological evidence that eating fish regularly does reduce ischemic heart disease)

31

Others

32

http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.short?rss=1&amp%3bssource=mfr

Part 2

Antianginal drugs

抗心绞痛药物

33

浙江大学医学院药理学系

张世红

shzhang713@zju.edu.cn

Outline

1 Overview of angina pectoris

2 Antianginal drugs

- Nitrate esters

- β-blockers

- Calcium channel blockers

3 Combination of antiganginal drugs

35

Leading Sources of Disease Burden*

• Ischemic Heart Disease

• Unipolar Major Depression

• Cardiovascular Disease

• Alcohol Use

• Traffic Accidents

• Lung and other cancers

• Dementia and Neurodegenerative Disorders

*based on DALY’s (Disability Adjusted Life Years, WHO) which measure lost years of healthy life due to premature death or disability

36

http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf

Sudden, uncomfortable pressure, fullness, squeezing or severe substernal pain, radiating to the left arm, shoulders, neck, etc.

Symptoms:

38

• Stable angina pectoris• Unstable angina pectoris

initial onset typeaccelerated typespontaneous type

angina at restVariant/Prinzmetal’s angina pectoris

• Mixed angina pectoris

Caused by atherosclerosis plaque and/orthrombus formation

Caused by spontaneous spasm of coronary arteries

Classification of angina pectoris:

39

Effort angina

Extreme weather

Excessive food intake Excessive smoking

ExerciseStrong emotion

Variant/Prinzmetal’s angina: usually occur when a person is at rest between midnight and 8am

Occurrence of stable and unstable angina pectoris

40

Demand of the myocardium for oxygen

Oxygen delivery to the myocardium by the coronary circulation

Normal Ischemia

How does angina pectoris happen?

41

动脉粥样硬化斑块

和血栓形成

冠脉痉挛

Decrease the oxygen demand and/or increase the delivery

BY

Strategies for angina treatment

- Dilating arteries, especially coronary arteries, including relieving spasm and opening collateral circulation

- Dilating veins

- Antiatherosclerosis and prevention of thrombosis

- Cardiac inhibition: decrease HR, contractility, tensility of myocardium

42

Quiz time

Which one of the following drugs does not show potential to treat stable angina pectoris?

A AtropineB NifedipineC PropranololD EnalaprilE Aspirin

Antianginal drugs

Nitrate esters (organic nitrates) β-receptor blockers Calcium channel blockers Other drugs (ACEIs, potacium

channel openers, molsidomine吗多明)

44

Nitroglycerin（硝酸甘油）

Isosorbide dinitrate（硝酸异山梨酯，消心痛）

Isosorbide mononitrates（单硝酸异山梨酯）

Actions• Dilate vessels:

- Dilate veins (small doses) and arteries, decrease pre/after-load and cardiac oxygen demand- Dilate coronary arteries, epicardial vessels and open collateral circulation, redistribute blood to ischemic area- Decrease LVFP, increase blood to subendocardial area

• Protect myocardial cells against ischemic injury• Anticoagulation of platelets

Nitrate esters（硝酸酯类）

45

46

Organic nitrates

47

Nitroglycerin

Isosorbide dinitrate

Time to peak effect

Duration of action

Pharmacokinetics

2 min

25 minSublingual

15 min

1 hourSublingual

Organic nitrates

48

硝酸异山梨酯

Clinical uses

Angina pectoris Acute myocardial infarction Chronic heart failure Acute respiratory failure and pulmonary arterial

hypertension

49

Organic nitrates

Adverse effects

Symptoms due to vasodilation: headache, increase of intraocular pressure, postural hypotension, facial flushing and tachycardia

Allergy Methaemoglobinaemia (高铁血红蛋白血症，at

very high doses)

50

Organic nitrates

Tolerance Provision of daily “nitrate-free interval” To supplement –SH (food, drugs), Vc To inhibit RAAS and sympathetic system

Drug interactions (aware of severe hypotension) Antihypertensive drugs Alcohol and Viagra

51

Organic nitrates

Something’s Gotta Give

52

Story time

Propranolol, metoprolol, atenololActions

- Inhibit cardiac contractility, decrease O2 demand

- Increase blood supply to ischemic area: perfusion time ↑ (heart rate↓), vascular tone in normal tissues ↑

- Improve myocardial metabolism (FFA ↓)

53

β-blockers

Clinical uses:- stable and unstable angina pectoris,

especially associated with hypertension or arrhythmias, even with myocardial infarction.

- NOT used for variant angina.

54

β-blockers

Notices:AsthmaStart from small dosesWithdraw gradually (rebound phenomenon)Combined with nitroglycerin when neededCardiac depression

55

Calcium channel blockers, CCBs

Actions contributing to antianginal effect :

- Decrease peripheral resistance and myocardial oxygen consumption- Increase myocardial blood supply: dilate coronary vessels, open collateral circulation- Protect ischemic myocardial cells by inhibiting Ca2+ overload- Inhibit coagulation of platelets

Clinic uses:• Angina pectoris

- Variant angina: ver, dil, nif- Stable angina: ver, dil, nif- Unstable angina: ver, dil, nif + β blockers

• Arrhythmias• Hypertension• Cerebrovascular diseases• Other diseases: peripheral vascular spasmodic

disease, arteriosclerosis, migraine

56

Calcium channel blockers, CCBs

Adverse effects:- peripheral edema- sympathetic

excitation (nif)- cardiac inhibition

(ver, dil)- hypotension (nif)

57

CCBs

Contraindications:- hypotension- severe heart failure- sinus bradycardia- atrioventricular

block

心肌耗氧因素 硝酸酯类β受体阻断药

CCBs硝苯地平 维拉帕米

硝酸酯类+ β受体阻断药

动脉压

心率

心肌收缩力 不变或降低

射血时间 不变

左室舒张末压 - 不变或降低

Combination of antianginal drugs

58

Rationality: O2 demand, adverse reactions

Caution：Hypotension, low cardiac perfusion

59

(ACEIs, β blocker, CCBs, Diuretics)